17,721 Shares in Alto Neuroscience, Inc. (NYSE:ANRO) Acquired by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Alto Neuroscience, Inc. (NYSE:ANRO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 17,721 shares of the company’s stock, valued at approximately $74,000. Skandinaviska Enskilda Banken AB publ owned about 0.07% of Alto Neuroscience at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC boosted its stake in Alto Neuroscience by 1.4% during the 3rd quarter. FMR LLC now owns 2,363,056 shares of the company’s stock worth $27,033,000 after acquiring an additional 32,040 shares during the last quarter. Franklin Resources Inc. boosted its stake in Alto Neuroscience by 95.3% during the 3rd quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock worth $13,965,000 after acquiring an additional 595,673 shares during the last quarter. Jennison Associates LLC boosted its stake in Alto Neuroscience by 80.3% during the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock worth $9,521,000 after acquiring an additional 370,612 shares during the last quarter. Vestal Point Capital LP lifted its stake in Alto Neuroscience by 4.8% in the third quarter. Vestal Point Capital LP now owns 650,000 shares of the company’s stock valued at $7,436,000 after buying an additional 30,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Alto Neuroscience by 148.7% in the third quarter. Geode Capital Management LLC now owns 469,988 shares of the company’s stock valued at $5,378,000 after buying an additional 281,018 shares in the last quarter.

Alto Neuroscience Trading Down 7.4 %

Shares of ANRO opened at $2.86 on Wednesday. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a twelve month low of $2.67 and a twelve month high of $18.35. The firm’s 50 day moving average price is $3.73 and its two-hundred day moving average price is $6.27.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.